Cetuximab sarotalocan

Cetuximab sarotalocan (RM-1929) is an IRdye700DX (near-infrared photosensitizing dye) conjugate of Cetuximab (anti-EGFR monoclonal antibody) . Cetuximab sarotalocan can be used for head and neck cancers research[1][2].

Product Specifications

CAS Number

[2166339-33-7]

Product Name Alternative

RM-1929; Cetuximab-IRDye-700DX

UNSPSC

12352203

Target

EGFR

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

[Cetuximabsarotalocan]

References & Citations

[1]Go Omura, et al. Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma. Auris Nasus Larynx. 2022 Jun 29; S0385-8146 (22) 00167-5. |[2]Isaku Okamoto, et al. Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers (Basel) . 2022 Sep 11;14 (18) :4413.